Crescent Biopharma (CBIO) executive compensation, 2026 proxy

Joshua Brumm, Chief Executive Officer & Director, was paid $13.1M in 2025.

Filed
April 21, 2026
Annual meeting
June 2, 2026
Pay year
2025
Named executives
3
CEO total pay
$13.1M2025
CEO pay in equity
92%$12M in awards
CEO Target Bonus Percentage
60%Percentage of base salary
CEO Stock Awards
$2,381,440Grant date fair value
CEO Option Awards
$9,635,227Grant date fair value
COO Base Salary
$550,000Annual base salary rate

How Brumm was paid

$13.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary4%Stock awards18%Option awards73%Non-equity incentive4%

Named executive officers

ExecutiveTotal
Joshua BrummChief Executive Officer & Director$13,116,834
Jonathan McNeill, M.D.Chief Operating Officer & President$6,604,328
Ellie Im, M.D.Chief Medical Officer$3,662,495

What changed and why

  • $13.1MJoshua Brumm received total compensation of $13,116,834 for fiscal year 2025 as chief executive officer.
  • Base salaries for named executive officers remained unchanged throughout the 2025 fiscal year.
  • Annual performance bonuses were awarded under the short-term incentive program based on above-target achievement.
  • Equity compensation included grants of both stock options and restricted stock units under company plans.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.